MA27065A1 - Composes inhibant la liberation des cytokines inflammatoires. - Google Patents

Composes inhibant la liberation des cytokines inflammatoires.

Info

Publication number
MA27065A1
MA27065A1 MA27568A MA27568A MA27065A1 MA 27065 A1 MA27065 A1 MA 27065A1 MA 27568 A MA27568 A MA 27568A MA 27568 A MA27568 A MA 27568A MA 27065 A1 MA27065 A1 MA 27065A1
Authority
MA
Morocco
Prior art keywords
substituted
inflammatory cytokines
release
unsubstituted
amines
Prior art date
Application number
MA27568A
Other languages
English (en)
Inventor
Michael Phillip Clark
Jane Far-Jine Djung
Matthew John Laufersweiler
Biswanath De
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27065A1 publication Critical patent/MA27065A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA27568A 2001-09-20 2004-03-10 Composes inhibant la liberation des cytokines inflammatoires. MA27065A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32362501P 2001-09-20 2001-09-20

Publications (1)

Publication Number Publication Date
MA27065A1 true MA27065A1 (fr) 2004-12-20

Family

ID=23259997

Family Applications (3)

Application Number Title Priority Date Filing Date
MA27569A MA27066A1 (fr) 2001-09-20 2004-03-10 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES CONTRôLANT LES CYTOKINES INFLAMMATOIRES.
MA27567A MA27064A1 (fr) 2001-09-20 2004-03-10 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones spirocycliques regulant les cytokines inflammatoires.
MA27568A MA27065A1 (fr) 2001-09-20 2004-03-10 Composes inhibant la liberation des cytokines inflammatoires.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA27569A MA27066A1 (fr) 2001-09-20 2004-03-10 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES CONTRôLANT LES CYTOKINES INFLAMMATOIRES.
MA27567A MA27064A1 (fr) 2001-09-20 2004-03-10 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones spirocycliques regulant les cytokines inflammatoires.

Country Status (33)

Country Link
US (2) US6566357B1 (fr)
EP (3) EP1427728B1 (fr)
JP (3) JP2005504082A (fr)
KR (4) KR100623879B1 (fr)
CN (3) CN1250551C (fr)
AR (3) AR037237A1 (fr)
AT (3) ATE356126T1 (fr)
AU (2) AU2002334641B2 (fr)
BR (3) BR0212905A (fr)
CA (3) CA2461073A1 (fr)
CO (3) CO5560590A2 (fr)
CY (1) CY1106398T1 (fr)
CZ (3) CZ2004361A3 (fr)
DE (3) DE60202782T2 (fr)
DK (2) DK1427732T3 (fr)
EG (2) EG24413A (fr)
ES (3) ES2282459T3 (fr)
HK (2) HK1071366A1 (fr)
HU (3) HUP0402378A3 (fr)
IL (3) IL160741A0 (fr)
MA (3) MA27066A1 (fr)
MX (3) MXPA04002569A (fr)
MY (2) MY129329A (fr)
NO (2) NO20041594L (fr)
NZ (3) NZ531123A (fr)
PE (3) PE20030474A1 (fr)
PL (3) PL370362A1 (fr)
PT (3) PT1427727E (fr)
RU (3) RU2272040C2 (fr)
SA (1) SA03230529B1 (fr)
SK (3) SK1502004A3 (fr)
WO (3) WO2003024973A1 (fr)
ZA (3) ZA200401260B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849627B2 (en) 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en) 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
CA2497007A1 (fr) * 2002-09-09 2004-03-18 Amgen Inc. Derives de 1, 4, 5-substitue 1, 2-dihydro-pyrazol-3-one et 3-alcoxy-1h-pyrazole, tnf-alpha et agents reduisant l'interleukine dans le traitement des inflammations
ATE361296T1 (de) * 2003-04-03 2007-05-15 Merck Patent Gmbh Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid) 2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
DK2432767T3 (da) * 2009-05-19 2013-09-30 Dow Agrosciences Llc Forbindelser og fremgangsmåder til at kontrollere svampe
EP3308059B1 (fr) 2015-06-15 2021-05-26 Cummins, Inc. Dispositif d'élasticité pour chambre de combustion
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN107033090B (zh) * 2017-05-16 2019-05-07 无锡捷化医药科技有限公司 一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) * 2019-09-06 2020-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
EP4422621A1 (fr) * 2021-10-27 2024-09-04 Merck Sharp & Dohme LLC Inhibiteurs de ripk1 spirotricycliques et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054291A (fr) * 1963-02-26
GB1124982A (en) * 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529154A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) * 1991-03-21 1994-10-25 Bayer Aktiengesellschaft 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
PT1481970E (pt) * 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
EG24363A (en) 2009-03-04
EG24413A (en) 2009-05-25
MY129329A (en) 2007-03-30
CY1106398T1 (el) 2011-10-12
CZ2004345A3 (cs) 2004-06-16
ZA200401403B (en) 2004-08-30
RU2004111803A (ru) 2005-10-10
EP1427727A1 (fr) 2004-06-16
DE60202782D1 (de) 2005-03-03
AR037145A1 (es) 2004-10-27
EP1427732A1 (fr) 2004-06-16
HK1071366A1 (en) 2005-07-15
BR0212716A (pt) 2004-08-03
CO5560589A2 (es) 2005-09-30
US20030105084A1 (en) 2003-06-05
RU2299885C2 (ru) 2007-05-27
DE60218704T2 (de) 2007-11-08
MA27066A1 (fr) 2004-12-20
KR20040035837A (ko) 2004-04-29
RU2272040C2 (ru) 2006-03-20
SA03230529B1 (ar) 2008-06-21
CA2461072A1 (fr) 2003-03-27
MXPA04002570A (es) 2004-05-31
BR0212905A (pt) 2004-10-13
US6821971B2 (en) 2004-11-23
PT1427727E (pt) 2005-06-30
AU2002327690B2 (en) 2006-07-20
KR100623879B1 (ko) 2006-09-19
SK1502004A3 (en) 2004-09-08
NZ531122A (en) 2005-09-30
AU2002334641B2 (en) 2007-03-29
CZ2004361A3 (cs) 2004-07-14
AR037237A1 (es) 2004-11-03
ES2268154T3 (es) 2007-03-16
RU2004111806A (ru) 2005-03-27
ZA200401260B (en) 2004-08-30
MA27064A1 (fr) 2004-12-20
SK1492004A3 (en) 2004-11-03
DK1427728T3 (da) 2007-07-09
KR20040035835A (ko) 2004-04-29
NZ531123A (en) 2006-08-31
KR20060036125A (ko) 2006-04-27
PE20030446A1 (es) 2003-07-21
HUP0500752A2 (en) 2006-01-30
DE60202782T2 (de) 2006-01-19
PL370415A1 (en) 2005-05-30
ZA200401402B (en) 2004-08-27
KR100656126B1 (ko) 2006-12-12
JP2005504083A (ja) 2005-02-10
CN1249066C (zh) 2006-04-05
ATE356126T1 (de) 2007-03-15
EP1427732B1 (fr) 2006-07-12
KR20040035836A (ko) 2004-04-29
ES2237691T3 (es) 2005-08-01
AR037502A1 (es) 2004-11-17
CO5560590A2 (es) 2005-09-30
IL160742A0 (en) 2004-08-31
HUP0402378A2 (hu) 2005-02-28
EP1427727B1 (fr) 2005-01-26
HK1071565A1 (en) 2005-07-22
BR0212673A (pt) 2004-08-24
WO2003024970A1 (fr) 2003-03-27
CA2461071A1 (fr) 2003-03-27
JP2005504081A (ja) 2005-02-10
PE20030474A1 (es) 2003-07-22
US6566357B1 (en) 2003-05-20
CN1257905C (zh) 2006-05-31
DE60218704D1 (de) 2007-04-19
ES2282459T3 (es) 2007-10-16
CN1250551C (zh) 2006-04-12
SK1482004A3 (en) 2004-08-03
CA2461073A1 (fr) 2003-03-27
RU2278864C2 (ru) 2006-06-27
WO2003024971A1 (fr) 2003-03-27
PT1427732E (pt) 2006-12-29
IL160741A0 (en) 2004-08-31
NO20041605L (no) 2004-06-21
PT1427728E (pt) 2007-05-31
JP2005504082A (ja) 2005-02-10
MY129069A (en) 2007-03-30
WO2003024973A1 (fr) 2003-03-27
HUP0402500A2 (hu) 2005-03-29
RU2004111805A (ru) 2005-04-10
CN1555375A (zh) 2004-12-15
IL160682A0 (en) 2004-08-31
DE60213108T2 (de) 2007-02-08
HUP0402378A3 (en) 2008-10-28
CN1556811A (zh) 2004-12-22
HUP0402500A3 (en) 2008-10-28
MXPA04002569A (es) 2004-05-31
DK1427732T3 (da) 2006-10-30
CO5560579A2 (es) 2005-09-30
PL370351A1 (en) 2005-05-16
PL370362A1 (en) 2005-05-16
CN1555379A (zh) 2004-12-15
ATE332901T1 (de) 2006-08-15
MXPA04002574A (es) 2004-06-18
ATE287887T1 (de) 2005-02-15
PE20030430A1 (es) 2003-06-24
EP1427728A1 (fr) 2004-06-16
NO20041594L (no) 2004-06-21
EP1427728B1 (fr) 2007-03-07
CZ2004358A3 (cs) 2004-07-14
DE60213108D1 (de) 2006-08-24
NZ531063A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
HK1071366A1 (en) Compounds which inhibit the release of inflammatory cytokines
WO2003045929A1 (fr) Derive bicyclique, procede de production de ce derive et utilisation correspondante
EP1724262A4 (fr) Derive de 1-(2h)-isoquinolone
GB0005357D0 (en) Compounds
WO2002089800A3 (fr) Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
HK1051858A1 (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof.
MY134226A (en) 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
NO20023298D0 (no) Nye imidazolderivater
MY139258A (en) Carbamoyl-type benzofuran derivatives
CA2377233A1 (fr) Intermediaires pour la synthese de composes de benzimidazole et procede de preparation
NO20041601L (no) Forbindelse som hemmer frigjøringen av inflammatoriske cytokiner
NO20021162L (no) 5-aminoalkyl og 5-aminokarbonyl-substituerte indoler
ATE262522T1 (de) Benzimidazolverbindungen
NO20062187L (no) Furanderivat som EP4-reseptorantagonister